



NIRMALA COLLEGE OF PHARMACY MUVATTUPUZHA



NATIONAL CONFERENCE

Nano-based Drug Delivery Systems; Recent Developments and Future Prospects

7 OCTOBER 2023

ASSOCIATING PARTNERS

INDIAN PHARMACEUTICAL ASSOCIATION



**JOURNAL OF INNOVATIONS IN
APPLIED PHARMACEUTICAL SCIENCES**



**INNOVATION AND
ENTREPRENEURSHIP
DEVELOPMENT CENTRE**



**INSTITUTION'S
INNOVATION
COUNCIL**
(Ministry of HRD Initiative)



HOME / ARCHIVES / Volume-8, Issue-3-S, 2023



National Conference on Nano-based Drug Delivery Systems; Recent Developments and Future Prospects conducted by Nirma College of Pharmacy, Muvattupuzha, in association with Indian Pharmaceutical Association on 7 October 2023

RESEARCH ARTICLE(S)

ASSESSMENT OF PHYSICAL FUNCTIONING IN RHEUMATOID ARTHRITIS PATIENTS AFTER RITUXIMAB THERAPY USING HEALTH ASSESSMENT QUESTIONNAIRE-DISABILITY INDEX

ANNA MARIA JOY , AKSHARA SHAJI , SHANIYA MATHEW , DR.SUJA ABRAHAM Pages 1-4

[VIEW PDF](#)

TOXICITY PROFILE OF CHEMOTHERAPY REGIMENS FOR MULTIPLE MYELOMA PATIENTS USING CTCAE CRITERIA

ANTONY V R, ARPITH ANTONY, HELAN KURIAN, JEEVA ANN JIJU, TIMY THOMAS, JITHIN SUNNY, SUJA ABRAHAM Pages 5-7

[VIEW PDF](#)

ISOLATION OF EMBELIN FROM EMBELIARIBES BERRIES FOR THE DEVELOPMENT OF TOPICAL ANTI-INFLAMMATORY PREPARATION

DR. R. BADMANABAN, MARIA S.PADATHIL , HANNA PARVEEN, DONA MERIN JOY, SHAHANA MAJEED, JOYCYMOLS, DR. DHRUBO JYOTI SEN Pages 8-18

[VIEW PDF](#)

DESIGN AND CHARACTERISATION OF TOPICAL EMULGEL CONTAINING NEEM OIL FOR ITS ANTIDANDRUFF PROPERTIES

EBY GEORGE, DR DHANISH JOSEPH, ABITHA N JABBAR, KHANSA BEEGAM M A, NIMISHA JOSEPH, MAHIMA FRANCIS, ANJU BOBAN, ANN MARIA ALEX Pages 19-23

[VIEW PDF](#)

DEVELOPMENT OF IMPLANTABLE DRUG DELIVERY SYSTEM OF EMBELIN FOR THE TREATMENT OF BREAST CANCER

RINCY. K. K, DR. DHANISH JOSEPH, BINSHA URUMEEES, ANN MARIYA JOSE, ATHIRA ANILAN Pages 24-28

[VIEW PDF](#)

COMPARATIVE INSILICO DOCKING STUDY INVOLVING ANTAGONISTIC ACTIVITY OF COUMARINDERIVATIVES ON EGFR AND CDK2

RIYA ANN THOMAS, EVA SARA SUNIL, ANNA ABEL FERNANDEZ, SOORYA ANIL, ANJANA ANTONY, ANN MARIA DAVIS, GODWIN THOMAS, SARANYA T S, GREESHMA SREERAM, DR. ELIZABETH ABRAHAM P Pages 29-35

[VIEW PDF](#)

ASSESSMENT OF PATIENT KNOWLEDGE, PRACTICE AND ADVERSE EVENTS OF INSULIN ADMINISTRATION AND STORAGE TECHNIQUES IN PATIENTS WITH DIABETES

ANTRIYA ANNIE TOM, NAMITHA ANTONY, PAVITHRA ASHOK, MUHAMMAD ABDUL KHADIR PS, JUHY JOJO Pages 42-46

[VIEW PDF](#)

FORMULATION AND EVALUATION OF HERBAL AFTERSHAVE GEL

CELU MARIYA FRANCIS, RIYA GEORGE, ANASWARA SANKAR, ANCY I J, MANJU MARIA MATHEWS, BADMANABAN R Pages 47-50

[VIEW PDF](#)

EVALUATION OF ANTIMICROBIAL ACTIVITY OF A HERBAL MIXTURE

DEEPA JOSE , SINI BABY, SUJJALA SUBASH, GIFTY LAWRENCE, ANEESA ANOOB , LINTA JOSE Pages 59-63

[VIEW PDF](#)

ONLINE SUBMISSION



Online ISSN:2455-5177

CODEN (CAS-USA): JIAPAW

Impact Factor: 5.832

Journal Archived in



KEYWORDS



CURRENT ISSUE

- ATHN 1.0
- ISS 2.0
- ISS 1.0

INFORMATION

- For Readers
- For Authors
- For Librarians

[Flag Counter](#)



EFFICIENT MICROWAVE SYNTHESIS OF COUMARIN DERIVATIVES WITH EVALUATION OF THEIR ANTIOXIDANT AND ANTI-INFLAMMATORY PROPERTIES
ANZIYA P A, SARANYA T S, ANJALI K, ANJALI KRISHNA, SINI BABY, DIVINE P DANIEL Pages 124-130
[VIEW PDF](#)

COSMETIC USE RELATED ADVERSE EVENTS AND NEED FOR COSMETOVIGILANCE
MERRIN JOSEPH, KARISHMA SHAJI, MAHIN T M, NANDANA P B, KRISHNA DAS Pages 64-71
[VIEW PDF](#)

A RETROSPECTIVE STUDY OF CLINICAL PROFILE OF VIPER BITE CASES IN SELECTED HOSPITALS IN CENTRAL KERALA
ANUMOL SAJU, ANTRIYA ANNIE TOM, ABY PAUL, SWAPNA SAJU, DONA JOHNSON, JESYLN JOE THOMAS, KUTTIKADEN Pages 72-74
JOY STEFFI, JOYAL M JOLL
[VIEW PDF](#)

FORMULATION AND EVALUATION OF HERBAL TOOTHPASTE CONTAINING EUPATORIUM TRIPLINERVISLEAF EXTRACT
VIDYA PETER, ROSNA BABU , SHERRY SEBASTIAN, ANGEL JAEMON, ANGEL JAEMON, ANAGHA V T, JEEVAN SAJEEV Pages 36-41
[VIEW PDF](#)

IN VITRO SCREENING OF ICACINACEOUS PLANTS INDIGENOUS TO KERALA
DR.ELIZABETH ABRAHAM P, FRINTO FRANCIS, PRADEEP R NAIR, ATHUL RAJ, RAJI RAJAN, ANAMIKA K. NAIR, PROF.DR.BADMANABAN.R Pages 51-58
[VIEW PDF](#)

FORMULATION AND EVALUATION OF BUCCAL FILM OF AN ANTIHYPERTENSIVE DRUG
ASHINAA BENEDICT, IRIN ROSE PAUL, DR. MANJU MARIA MATHEWS, DR. BADMANABAN R Pages 75-80
[VIEW PDF](#)

A PROSPECTIVE SURVEY TO ASCERTAIN THE SYMPTOMS, HEALTH ISSUES AND SUBSEQUENT OTC MEDICATION USAGE DURING MENSTRUATION AMONG COLLEGE STUDENTS
MINTU GEORGE, ANAGHA MELBIN, MARY PAUL DOMINIC, RESHMA DOMINIC, AYSHA SAJA P.S, JOBIN KUNJUMON Pages 81-84
VILAPURATHU
[VIEW PDF](#)

A CROSS SECTIONAL STUDY TO ANALYSE THE ADR REPORTED IN A HOSPITAL DURING THE PAST THREE YEARS
SANGEETHA SUKUMARAN, VARSHA ELIZABETH JOBY, AMALA JOSEPH, APARNA JESTIN, JITHIN N P, SUMAYYA B Pages 85-89
MUHAMMED, SUNU SEBASTIAN, JOBIN KUNJUMON VILAPURATHU
[VIEW PDF](#)

FORMULATION AND EVALUATION OF PREUNGUAL DELIVERY SYSTEM CONTAINING EUGENOL FOR THE TREATMENT OF ONYCHOMYCOSIS
MINI ELIAS, FLOWERLET MATHEW, GOURISREE T, ANILA RAJAN, ASHLY DAVIS Pages 90-94
[VIEW PDF](#)

FORMULATION AND EVALUATION OF FLOATING CONTROLLED DRUG DELIVERY OF ANTI-ULCER DRUG LOADED MICROBALLOONS
BINDUMOL K C, FLOWERLET MATHEW, SHALOM SUNIL, ANGEL JOSE Pages 95-100
[VIEW PDF](#)

PREPARATION AND EVALUATION OF FLOATING DRUG DELIVERY SYSTEM (FDSD) CONTAINING AN ANTIVIRAL DRUG
TEENA MOHAN, MARIYA SUNNY, MANJU MARIA MATHEWS, BADMANABAN R Pages 105-109
[VIEW PDF](#)

FORMULATION AND EVALUATION OF CONTROLLED POROSITY ORAL OSMOTIC PUMP TABLETS OF FUROSEMIDE
TEENA CHACKOCHEN THEKKAL, REBA RENJU, MANJU MARIA MATHEWS, BADMANABAN R Pages 110-113
[VIEW PDF](#)

FORMULATION AND EVALUATION OF TOPICAL GELS INCORPORATED WITH SOLID DISPERSIONS OF AN ANTIINFLAMMATORY DRUG
SETHU LEKSHMI, THERASE JOSE, MANJU MARIA MATHEWS, BADMANABAN R Pages 114-119
[VIEW PDF](#)



IN VITRO ANTI-BACTERIAL SCREENING OF DRYNARIYA QUERCIFOLIA

ASHNA T, LINS MARY JOY, SIYARA ANTONY, SINDU T J, SHEEBA MOL P, SHUJI T S, SOUMYA K GEORGE

Pages 120-123

[VIEW PDF](#)

CASE REPORT(S)

GUILLAIN-BARRE SYNDROME: A PAEDIATRIC CASE SCENARIO IN A TERTIARY CARE HOSPITAL AT SOUTHERN INDIA

NEVIN JOSEPH, ALFIN BABY, ELDBOSE ELIAS GEORGE, GOPIKRISHNAN T.S, MERRIN JOSEPH

Pages 101-104

[VIEW PDF](#)

[Announcements](#) || [Editorial Board](#) || [Indexing](#) || [Contact](#)

The publication is licensed under a [Creative Commons License \(CC BY-NC\)](#). [View Legal Code](#)

Copyright © 2023, JIAPSONline





Journal of Innovations in Applied Pharmaceutical Science [JIAPS]

Content available at: www.saap.org.in ISSN: 2455-5177



GUILLAIN-BARRE SYNDROME: A PAEDIATRIC CASE SCENARIO IN A TERTIARY CARE HOSPITAL AT SOUTHERN INDIA

Nevin Joseph¹, Alfin Baby¹, Eldhose Elias George¹, Gopikrishnan T.S¹, Merrin Joseph*²

¹PharmD Intern, Nirmala College of Pharmacy, Muvattupuzha, Kerala, India

²Asst. Professor, Dept. of Pharmacy Practice, Nirmala College of Pharmacy, Muvattupuzha, Kerala, India, 686661

Article History

Received: 06-10-2023

Revised: 26-10-2023

Accepted: 17-10-2023

Keywords: Guillain-Barre Syndrome, GBS, Case Study, Treatment, Antibody, Polyneuropathy



Abstract

Background: During hospital a ward round which was conducted as a part of Doctor of Pharmacy curriculum at Caritas Hospital, Thellakom, the first author got a chance to deal with a case of GBS.

Case: 12 year old female patient admitted with complaints of weakness on both legs; later diagnosed by the neurologist with demyelinating poly neuropathy and Guillain-Barre Syndrome. **Aim:** The aim of this particular study was to study more about Guillain-Barre Syndrome which is an auto immune disorder involving peripheral nervous system which usually occurring very rarely, affects 1.55 people per 100,000 in the world's population, and is characterised by flaccid paralysis of limbs. It typically happens as a result of an earlier illness or other triggering events that excite the immune system of the body and result in the development of various antibodies.

Materials and Methods: Analyse various case reports published in various scientific databases like PubMed, Medline, CrossRef etc.

Results: This particular case was treated as follows: The treatment involves intravenous infusion of IVIg at a dose which varies according to the weight and severity of condition in each individual. Supplementation with Methyl cobalamin, Alpha lipoic acid, Levo-carnitine, and Vitamin E can improve the neural health and hasten the healing of nerve injuries.

Conclusion: Data till now tells us that out of all GBS diagnosed population, 80% have recovered completely, 15% of patients have shown some neurological disabilities, and 5% have succumb to death. Here, the therapy was successful and the patient got discharged from hospital.

This article is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.

Copyright © 2023 Author[s] retain the copyright of this article.



*Corresponding Author

Merrin Joseph

<https://doi.org/10.37022/jiaps.v8i3-S.533>



Production and Hosted by

www.saap.org.in

Introduction

Evidences of involvement of the immune system after the occurrence of certain infections or sometimes after receiving vaccinations have been established. The specific source of this immune system activation is unclear. Gullain-Barre Syndrome, commonly known as Landry's paralysis, is such an immune-mediated inflammatory reaction of the neurological system, involving peripheral nervous system which usually affects 1.55 people per 100,000 in the world's population, and is characterised by flaccid paralysis of limbs [1]. It is either or not followed by an infection vaccination, or surgery. A typical triggering factor is often an infectious disease caused primarily by *Campylobacter jejuni*, which is the major cause, other pathogens include *cytomegalovirus* (CMV), Epstein-Barr

virus, *Mycoplasma pneumonia*, *Haemophilus influenza*, and *Influenza A* virus. People can also develop Guillain-Barre syndrome due to vaccines like a meningococcal vaccine, poliovirus vaccine, influenza vaccine, and rabies vaccine [1-2]. Subtypes of GBS include acute inflammatory demyelinating polyneuropathy (AIDP), Acute Motor Axonal Neuropathy (AMAN), Acute Motor Sensory Axonal Neuropathy (AMSAN), Pharyngeal-Cervical brachial variant and Miller Fisher Syndrome. AIDP is a sensorimotor GBS that is frequently associated with cranial nerve abnormalities and autonomic dysfunction. It is caused by a variety of antibodies. AMAN is purely a motor involving GBS comprising antibodies like GM1a, GM1b, GD1a, GaINAc-GD1a. In case of AMAN cranial nerves are less affected. AMSAN resembles severe AMAN with sensory fibre damage and is mediated by GM1, GD1a antibodies. Motor fibres are damaged in Acute Motor and Sensory Axonal Neuropathy (AMSAN), which might be regarded a severe form of AMAN. Miller Fisher Syndrome (MFS) is a rare variant of GBS characterized by paralysis of the muscles within or surrounding the eye, the loss of full control of bodily movements and the absence of deep tendon reflexes. In most patients, diplopia is the presenting symptom. Patients with MFS usually have a good clinical outcome but rarely some of t

he patients develop limb weakness and respiratory insufficiency (termed MFS-GBS overlap syndrome). Other local variants of GBS, such as the pharyngeal-cervical-brachial variant, have also been reported [3].

The pathophysiology behind occurrence of GBS after an infection can be described as below: After *C. jejuni* infection, antibodies are generated and these antibodies cross react with specific gangliosides, like GM1 and GD1a on peripheral nerves. The antigens targeted in AMAN (Acute Motor Axonal Neuropathy) are seen at or near the node of Ranvier. In response to the anti-GM1 and anti-GD1a antibodies binding to the nodal axolemma, complement is activated, MAC is formed, and voltage-gated sodium channels vanish. This injury causes para-nodal myelin separation, which leads to failure of nerve conduction. Macrophages then infiltrate the peri-axonal area from those nodes, roaming the damaged axons. Antigens on the myelin sheath are targeted in AIDP (Acute Inflammatory Demyelinating Polyneuropathy). In brief, antibodies that activate the complement system cause the development of the MAC on the outer surface of Schwann cells, causing vesicular degeneration and macrophage invasion of myelin [4].

Most common symptoms are the weakness of the legs (areflexia) and paralysis, accompanied by tingling dysesthesias in lower extremities or even pain (especially in children), often starting in the legs or back. Insufficient respiration necessitating artificial ventilation may develop, autonomic dysfunction (most often cardiovascular dysregulation) may also happen to occur.

Diagnosis is based on symptoms such as bilateral weakness, rapid progression, and hypo/areflexia. Blood tests are not required to diagnose this pathology. Nerve conduction studies (NCS) are the only way to diagnose GBS and distinguish between axonal and demyelinating subtypes. After 2 weeks of paralysis, nerve conduction problems tend to peak. GBS subtypes have different abnormalities. NCS exhibits demyelination-related characteristics in AIDP, such as extended distal motor latency, decreased nerve conduction velocity, prolonged F-wave latency, increased temporal dispersion, and conduction block. Whereas reduced motor and/or sensory amplitudes without demyelinating characteristics are seen in axonal GBS (AMAN or AMSAN). Additionally, sensory-nerve studies will be performed to help distinguish between AMAN and AMSAN, whereas neurophysiological findings in AMAN are very complex, indicating transient conduction block or slowing that quickly recovers during the course of the disease—a phenomenon known as reversible conduction failure; which is not present in AMSAN. However, reversible conduction failure might be mistaken for demyelination, as antiganglioside antibodies can cause reduced conduction at the node of Ranvier. As a result, patients with reversible conduction failure may be misdiagnosed with AIDP rather than AMAN. To avoid such scenarios, serial NCS may be required. Compound Muscle Action Potential (CMAP) scanning, a new electrophysiological method, has improved the diagnosis even further [3-4].

Treatment mainly includes administration with IVIg which inhibits Fc-mediated immune cell activation. Serum IgG-Fc glycosylation in GBS patients appears to be linked to illness severity and may impact IVIg immunomodulatory effect. When administered at a dose of 0.4 g/kg daily for 5 days (

g/kg daily for 2 days) within 2 weeks after the onset of weakness, it is helpful in those who are unable to walk 10 metres on their own and have a GBS Disability Scale score of 3. Alternative therapeutic options for antibody treatment include plasma exchange, which eliminates neurotoxic antibodies, complement factors, and other humoral inflammatory mediators. Supportive therapy for respiratory distress should be provided in the form of oxygen supplementation in addition to the primary treatment. Chances for occurrence of DVT and pulmonary embolism are there; thus Low molecular weighted Heparin can be given prophylactically. Treatment-related fluctuation (TRF) is deterioration after initial improvement or stability that generally improves following treatment with IVIg or plasma exchange; in patients who develop TRF, a retreatment with IVIg (2 g/kg over 5 days) is recommended.

Data till now tells us that out of all GBS diagnosed population, 80% have recovered completely, 15% of patients have shown some neurological disabilities, and 5% have succumb to death. We witnessed a scenario of a young girl who acquired paralysis in both lower limbs without any preceding illness, immunisation, or surgery, at a tertiary care hospital.

Case Details

A 12 year old female patient was admitted in the hospital with chief complaints of weakness on both lower limbs. The patient admitted with fever, body ache on exertion and buckling of legs, four days ago. The patient came by walking, accompanied by relative. The breathing was adequate and level of consciousness was good. The patient was vulnerable and the risk on full assessment found to be low. The patient was having a past history of hemiplegic migraine. On examination, B/L hand gripping, LL proximal 4- right, LL proximal 4-left, distal 4+. The patient was admitted in the neurological department.

Table no: 1 Laboratory investigations

PARAMETER	NORMAL	OBSERVED VALUE
Haematological Parameters		
Hb	12-17 gm/dl	13.7
Neutrophil	45-75 %	52
Lymphocyte	20-40 %	43
Monocyte	2-10 %	2
Basophil	0-1 %	0
Eosinophil	1-6 %	3
ESR	0-22 mm/hr.	11
Platelet	1.5-4 Lcells/cu.mm	3.25
Liver Function Test		
Total protein	6-8 mg/dL	7.3
S. Albumin	3.5-5 mg/dL	4.4
SGOT	10-40IU/L	21
SGPT	10-37 IU/L	14
Total bilirubin	0.3-1 mg/dL	0.5
ALP	20 to 140 IU/L	216
Renal Function Tests		
Blood urea	10-50 mg/dL	21.9
S. Creatinine	0.6-1.1 mg/dL	0.5
S. Sodium	130-145mEq/L	135

S. potassium	3.5-5.4mEq/L	4.2
CPK	55-170 U/L (M) 30-135 U/L (F)	27
Thyroid Function Tests		
TSH	0.5 to 5.0 mIU/L	1.66




Figure 1: Nerve Conduction Study Report

Nerve Conduction Study Report

Studies done and was found that bilateral peroneal distal latency was prolonged, F waves were absent in bilateral peroneals and the results were suggestive of demyelinating polyneuropathy. (From Figure 1)

Diagnosis

The person was identified as having demyelinating polyneuropathy and GBS after examining the findings of nerve conduction testing and other laboratory parameters.

Treatment

The neurologist advised to maintain the oxygen saturation above 95% all the time. Inj. Hydrocortisone 100mg and phenaramine maleate 1ml was given as IV stat. The patient

was admitted for 9 days. And during hospital stay, the patient was treated with IVIG infusion and other supportive care. IVIG infusion was given at a rate of 50 ml/hr.; 20gm twice a day for 5 days, followed by 10 gm infusion once on the next day. Along with IVIG infusion an injection containing pyridoxine hydrochloride 100mg, Mecobalamin 1000mcg and Nicotinamide 100mg was given once for first five days. From the fourth day, tablet containing alphalipoic acid (100 mg), mecobalamin (1500 mcg), folic acid (1.5 mg), pyridoxine (3 mg) and Cholecalciferol (1000 IU) was given at noon; even after discharge. And from the day six, tablet containing Levocarnitine (150mg) + Vitamin E (200mg) was given once daily as a drug to be continued thereafter. The patient was also advised with Diclofenac gel to be applied in the area where an algia is felt twice a day.

Discussion

Acute monophasic demyelinating neuropathy (GBS), which causes increasing are flexia and motor weakness in the limbs, is what is known as the condition (Lack of motor reflex). The areas we need to focus comprises of symptomatic manifestations, laboratory investigation reports, treatment regimen and final therapeutic outcome. The primary goal of the therapy is to improve the patient's clinical condition and to improve the patient's standard of life. Normally, GBS is manifested as rapidly evolving is flexic motor paralysis with or without sensory disturbance, usually an ascending flaccid paralysis. Sensory impairments such as numbness and/or paraesthesia are more commonly reported in leg muscles than in arms. Pain is usually accompanied. And in this case too, the subject came with similar clinical findings, especially the weakness of limbs and pain with minor sensory and motor neural conduction deficits. Now, as you can see in the laboratory parameters, the ALP is elevated (From Table 1). But, ALP levels will be higher in girl children with ages near to age 12 and they start to decline after 12 years. This happens so because their bones are in the growth phase at this age. This rise in ALP in this case is insignificant. But, if similar case arises in case of an adult indicates the chances of Heterotopic Ossification (HO), which a metabolic disorder, characterized by new lamellar bone formation outside the normal skeletal structure; which is a rare complication of GBS. It is to be noted again that the CPK (Creatinine Phosphokinase) values for children lies between 27 to 170 IU/L; thus here too, the value remains in the normal range. (From Table 1)

Regarding the available treatments, as we have already mentioned, the standard of care entails the administration of IVIg, which prevents the Fc-mediated activation of immune cells connected to the formation of antiganglioside antibodies. The normal dosing of IVIg in GBS is a single dose of 0.4 g/kg IVIg every day for 5 successive days. In this particular scenario, to the patient during her hospital stay was given with IVIG infusion and other supportive care. IVIG infusion was given at a rate of 50 ml/hr.; 20gm twice a day for 5 days, followed by 10 gm. infusion once on the next day. For an average girl of age 12 years, the body weight lies in between 40-50 kg. The weight of the subject being approximately equal to 50kg the dose was appropriate; and to reduce the chances of TRF, a secondary dose of IVIg was given after five days of treatment. Since it is known that MeCbl improves nerve conduction, promotes the

regeneration of damaged or injured nerves, and inhibited ectopic spontaneous discharges of injured primary sensory neurons.8 Alpha lipoic acid being a good antioxidant, it can help with controlling harmful free radicle oxidation of nerve cells; further reducing the rate of demyelination.9Levo-carnitine highly appreciated for its analgesic and nerve fibre cluster regeneration, by inhibiting prostaglandin synthesis and lipid peroxidation- is given her for the same reason as mentioned.10 Vitamin E which is essential for normal neurological function, increases the integrity of membranes by inhibiting lipid peroxidation and enhances the rate of cellular regeneration after damage [11].

Conclusion

Acute monophasic demyelinating neuropathy, often known as Guillain-Barre Syndrome (GBS), is a disorder that causes increasing areflexia and motor weakness in the limbs (Lack of motor reflex). And in this case report, the subject was a female having 12 year old, who came with complaints of weakness on both lower limbs. The subject's motor nerve conduction studies were done and was found that bilateral peroneal distal latency was prolonged, F waves were absent in bilateral peroneals and the results were suggestive of demyelinating polyneuropathy. Treatment includes administration with IVIg which inhibits Fc-mediated activation of immune mediated cells. Serum IgG- Fc glycosylation in GBS patients appears to be intimately associated with severity of disease and can influence the immuno-modulatory effects of IVIg. When given within two weeks after the commencement of weakness, at a dose of 0.4 g/kg daily for five days (or 1 g/kg daily for two days), a better treatment effect was seen. The weight of the subject being approximately equal to 50kg the dose was appropriate; and to reduce the chances of TRF, a secondary dose of IVIg was given after five days of treatment. Along with the primary treatment regimen, since it is known that MeCbl, Alpha lipoic acid, Levocarnitine, and Vitamin E improves nerve conduction, promotes the regeneration of damaged or injured nerves, those supplementations were also given. Data till now tells us that out of all GBS diagnosed population, 80% have recovered completely, 15% of patients have shown some neurological disabilities, and 5% have succumb to death. The treatment was successful and the subject has recovered. Thus, the personnel was discharged.

Acknowledgement

We would like to thank Dr. Joseph Sebastian MBBS, MD (medicine), DM (neurology), Fellowship in Cerebrovascular Diseases and other hospital authorities for their collaboration. This was not an industry supported study. The authors do not make any recommendations to use drugs or devices off-label.

Conflict of Interest

Authors have no conflict of interest to declare.

Abbreviations

GBS: Guillain-Barre syndrome

NCS: Nerve Conduction Study

AMAN: Acute Motor Axonal Neuropathy

AMSAN: Acute Motor-Sensory Axonal Neuropathy

AIDP: Acute Inflammatory Demyelinating Polyradiculopathy

MFS: Miller Fisher Syndrome

MeCbl: Methyl cobalamin

Hb: Haemoglobin

SGOT: Serum Glutamic-Oxaloacetic Transaminase

SGPT: Serum Glutamic-Pyruvic Transaminase

ALP: Alkaline Phosphatase

CPK: Creatine Phosphokinase

CMAP: Compound Muscle Action Potential

TRF: Treatment-Related Fluctuation

IVIg: Intravenous Immuno-Globulin

DVT: Deep Vein Thrombosis

References

1. Scheidl E, Canseco D, Hadji-Naumov A, Bereznai B. Guillain-Barré syndrome during SARS-CoV-2 pandemic: A case report and review of recent literature. *Journal of the Peripheral Nervous System*. 2020;25(2):204-207.
2. Wajih Ullah M, Qaseem A, Amray A. Post Vaccination Guillain Barre Syndrome: A Case Report. *Cureus*. 2018;.
3. Kumar M. Guillain-Barré Syndrome: A Clinical Study of Twenty Children. *JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH*. 2015;.
4. van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs B, van Doorn P. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. *Nature Reviews Neurology*. 2014;10(8):469-482.
5. Penrose N. Guillain-Barré Syndrome: A Case Study. *Rehabilitation Nursing*. 1993;18(2):88-90.
6. A. A. Amato, "Guillain Barre Syndrome and Related Disorders," *Revista Mexicana de Neurociencia*, Vol. 6, No. 5, 2005, pp. 455-469.
7. Zeilig G, Weingarden H, Levy R, Peer I, Ohry A, Blumen N. Heterotopic Ossification in Guillain-Barré Syndrome: Incidence and Effects on Functional Outcome With Long-Term Follow-Up. *Archives of Physical Medicine and Rehabilitation*. 2006;87(1):92-95.
8. Zhang M, Han W, Hu S, Xu H. Methylcobalamin: A Potential Vitamin of Pain Killer. *Neural Plasticity*. 2013;2013:1-6.
9. Stevens M, Obrosova I, Cao X, Van Huysen C, Greene D. Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. *Diabetes*. 2000;49(6):1006-1015.
10. De Angelis C, Scarfò C, Falcinelli M, Perna E, Reda E, Ramacci M et al. Acetyl-L-carnitine Prevents Age-Dependent Structural Alterations in Rat Peripheral Nerves and Promotes Regeneration Following Sciatic Nerve Injury in Young and Senescent Rats. *Experimental Neurology*. 1994;128(1):103-114.
11. SEN C, KHANNA S, ROY S. Tocotrienol: The Natural Vitamin E to Defend the Nervous System?. *Annals of the New York Academy of Sciences*. 2004;1031(1):127-142.

